Biosense Webster

Diagnosis and Treatment of Cardiac Arrhythmias

Health Tech & Life Sciences
Acquired by Johnson & Johnson on Sep, 1997

Company Overview

Snapshot

Founded in September 1993, Biosense Webster operates with over 3,000 employees. The company was acquired by Johnson & Johnson in September 1997, marking a significant milestone in its trajectory within the health tech and life sciences sector.

Business overview

Biosense Webster develops advanced solutions for the diagnosis and treatment of cardiac arrhythmias, focusing on improving procedural methodologies and success rates for physicians. Its core technology includes CARTO Solutions, which provide navigational and mapping features, integrating multiple datasets and images into detailed, real-time information for patient care. The company serves the healthcare industry, specifically targeting cardiologists and hospitals with its medical devices, diagnostics, and therapeutic offerings.

Strategic signal

In October 2022, Biosense Webster launched HELIOSTAR™ in Europe, introducing the first radiofrequency Balloon Ablation Catheter designed to enable more efficient cardiac ablations. This development signals the company's continued innovation in cardiovascular medical devices, aiming to enhance treatment efficacy and expand its market presence in advanced cardiac care solutions.

Company Intelligence Q&A

What is Biosense Webster's primary focus?
Biosense Webster focuses on developing solutions for the diagnosis and treatment of cardiac arrhythmias, aiming to improve procedural methodologies and success rates for physicians.
When was Biosense Webster acquired?
Biosense Webster was acquired by Johnson & Johnson in September 1997.
What is the CARTO Solutions product?
CARTO Solutions are Biosense Webster's advanced 3D mapping modules that integrate multiple datasets and images to provide highly detailed, real-time information for physicians treating cardiac arrhythmias.
What significant product did Biosense Webster launch in October 2022?
In October 2022, Biosense Webster launched HELIOSTAR™ in Europe, which is the first radiofrequency Balloon Ablation Catheter designed for more efficient cardiac ablations.
What was the focus of Biosense Webster's September 2022 product launch?
In September 2022, Biosense Webster launched the OCTARAY™ Mapping Catheter with TRUEref™ Technology, enhancing its diagnostic capabilities for cardiac arrhythmias.

External links